Paper42459699
Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.
Wang T and 2 others. Front Immunol, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy. Papers, record 42459699. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42459699
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Tertiary lymphoid structures as biomarkers and therapeutic targets in neoadjuvant cancer immunotherapy.
- PubMed
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoadjuvant Therapy | Major topic |
| Tertiary Lymphoid Structures | Major topic |
| Immunotherapy | Major topic |
| Neoplasms | Major topic |
| Biomarkers, Tumor | Major topic |
| Humans | |
| Tumor Microenvironment | |
| Animals | |
| Immune Checkpoint Inhibitors |
Source PubMed
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38114518 | Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. | Nat Commun | 2023 | https://conductscience.org/library/papers/38114518 | PubMed |
| 2 | 29279354 | Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma. | Cancer Res | 2018 | https://conductscience.org/library/papers/29279354 | PubMed |
| 3 | 36056951 | The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study. | Cancer Immunol Immunother | 2023 | https://conductscience.org/library/papers/36056951 | PubMed |
| 4 | 35403841 | Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. | N Engl J Med | 2022 | https://conductscience.org/library/papers/35403841 | PubMed |
| 5 | 38012408 | Decoding the tumor microenvironment with spatial technologies. | Nat Immunol | 2023 | https://conductscience.org/library/papers/38012408 | PubMed |
| 6 | 38057283 | Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study. | Thorac Cancer | 2024 | https://conductscience.org/library/papers/38057283 | PubMed |
| 7 | 28899864 | Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. | Cancer Discov | 2017 | https://conductscience.org/library/papers/28899864 | PubMed |
| 8 | 37055640 | Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. | Nature | 2023 | https://conductscience.org/library/papers/37055640 | PubMed |
| 9 | 41972153 | Clinicopathological and molecular characteristics associated with pathological complete response in neoadjuvant immunotherapy for breast cancer. | Front Immunol | 2026 | https://conductscience.org/library/papers/41972153 | PubMed |
| 10 | 39314905 | Immune priming and induction of tertiary lymphoid structures in a cord-blood humanized mouse model of gastrointestinal stromal tumor. | Oncoimmunology | 2024 | https://conductscience.org/library/papers/39314905 | PubMed |
| 11 | 31092904 | Tertiary lymphoid structures in the era of cancer immunotherapy. | Nat Rev Cancer | 2019 | https://conductscience.org/library/papers/31092904 | PubMed |
| 12 | 33277370 | Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33277370 | PubMed |
| 13 | 38066335 | How chemokines organize the tumour microenvironment. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/38066335 | PubMed |
| 14 | 38458196 | An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure. | Cell Rep Med | 2024 | https://conductscience.org/library/papers/38458196 | PubMed |
| 15 | 38340557 | Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancer. | EBioMedicine | 2024 | https://conductscience.org/library/papers/38340557 | PubMed |
| 16 | 35969830 | Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/35969830 | PubMed |
| 17 | 36795255 | Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. | Ann Surg Oncol | 2023 | https://conductscience.org/library/papers/36795255 | PubMed |
| 18 | 31942075 | B cells and tertiary lymphoid structures promote immunotherapy response. | Nature | 2020 | https://conductscience.org/library/papers/31942075 | PubMed |
| 19 | 37870974 | Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer. | N Engl J Med | 2023 | https://conductscience.org/library/papers/37870974 | PubMed |
| 20 | 32001626 | Neoadjuvant checkpoint blockade for cancer immunotherapy. | Science | 2020 | https://conductscience.org/library/papers/32001626 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42787593 | Tertiary lymphoid structures in neoadjuvant and perioperative cancer immunotherapy: a review and proposed framework for biomarker interpretation and validation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42787593 | PubMed |
| 42724854 | Combined multi-omics profiling and machine learning analysis reveals that Bregs and RPS2 promote bone metastasis in nasopharyngeal carcinoma. | Transl Cancer Res | 2026 | https://conductscience.org/library/papers/42724854 | PubMed |
| 42598915 | TLS as Predictors and Targets in Neoadjuvant Chemoimmunotherapy for NSCLC. | Thorac Cancer | 2026 | https://conductscience.org/library/papers/42598915 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42459699
GET https://conductscience.org/api/papers/v1/42459699/references?page=2